Neumora Therapeutics (NASDAQ: NMRA)

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Alto Neuroscience

This biopharmaceutical company develops precision medicines for patients with neuropsychiatric conditions by using an artificial intelligence platform to analyse brain-based biomarkers.

Engrail Therapeutics

This company develops small-molecule therapies for patients with neurologic, neuropsychiatric and neurodevelopmental disorders such as anxiety, depression and rare diseases.

Engrail

This clinical-stage pharmaceutical company develops targeted small-molecule medicines for patients with neuropsychiatric and neurodevelopmental disorders.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Cerevel Therapeutics

This biopharmaceutical company develops neuroscience medicines for patients with mental and neurological conditions including schizophrenia, Parkinson's disease and epilepsy.

Noema Pharma

This company develops clinical-stage therapeutic products for patients with central nervous system disorders and orphan neurological conditions.

Athira Pharma

This biopharmaceutical company develops small molecule therapies for patients with neurodegenerative conditions and certain cancers.